<p>Non-sputum–based diagnostics using readily available clinical samples represent an urgent need in the effort to improve tuberculosis (TB) detection and control. This study evaluated urine as a non-invasive alternative by isolating urinary extracellular vesicles (uEVs), which may facilitate the enrichment of <i>Mycobacterium tuberculosis</i> (Mtb) antigens including MPT-64 and lipoarabinomannan (LAM) being detected in this study. A total of 162 participants were enrolled, including pulmonary TB (PTB) patients (<i>n</i> = 54), latent TB infection (LTBI) subjects (<i>n</i> = 33), other respiratory disease (ORD) controls (<i>n</i> = 58), and healthy controls (<i>n</i> = 17). The uEVs were characterized using nanoparticle tracking analysis, transmission electron microscopy, and western blotting, and subsequently analyzed by real-time immuno-PCR (RT-I-PCR) for simultaneous detection of MPT-64 and LAM. The assay demonstrated ultralow limit of detection (LOD) for purified MPT-64 + LAM (9.7&#xa0;fg/mL), markedly outperforming indirect ELISA (3.7 ng/mL). Clinically, RT-I-PCR demonstrated 94.44% sensitivity in bacteriologically confirmed PTB, detecting all smear- and/or culture-positive cases and 86.96% of smear- and culture-negative but GeneXpert-positive cases, with an overall specificity of 90.74% among the control groups. In comparison, indirect ELISA identified only 31.48% of bacteriologically confirmed PTB cases while maintaining a high specificity of 96.15%. Receiver operating characteristic (ROC) curve analysis of RT-I-PCR assay indicated high diagnostic accuracy, with area under the curve (AUC) values ranging from 0.9741 to 0.9847. These findings highlight the potential of uEVs-based RT-I-PCR as a highly sensitive, non-invasive approach for PTB diagnosis, while emphasizing the need for further evaluation in larger and more diverse clinical cohorts to develop a scalable, non-invasive diagnostic platform suitable for TB-endemic settings.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Detection of Mycobacterium tuberculosis antigens in urinary extracellular vesicles using real-time immuno-PCR: A non-invasive diagnostic approach for pulmonary tuberculosis

  • Ayushi Kaur Bedi,
  • Bhawna Dahiya,
  • Monika Sharma,
  • Parul Mrigpuri,
  • Nitin Goel,
  • Mandira Varma-Basil,
  • Promod K. Mehta,
  • Sadhna Sharma

摘要

Non-sputum–based diagnostics using readily available clinical samples represent an urgent need in the effort to improve tuberculosis (TB) detection and control. This study evaluated urine as a non-invasive alternative by isolating urinary extracellular vesicles (uEVs), which may facilitate the enrichment of Mycobacterium tuberculosis (Mtb) antigens including MPT-64 and lipoarabinomannan (LAM) being detected in this study. A total of 162 participants were enrolled, including pulmonary TB (PTB) patients (n = 54), latent TB infection (LTBI) subjects (n = 33), other respiratory disease (ORD) controls (n = 58), and healthy controls (n = 17). The uEVs were characterized using nanoparticle tracking analysis, transmission electron microscopy, and western blotting, and subsequently analyzed by real-time immuno-PCR (RT-I-PCR) for simultaneous detection of MPT-64 and LAM. The assay demonstrated ultralow limit of detection (LOD) for purified MPT-64 + LAM (9.7 fg/mL), markedly outperforming indirect ELISA (3.7 ng/mL). Clinically, RT-I-PCR demonstrated 94.44% sensitivity in bacteriologically confirmed PTB, detecting all smear- and/or culture-positive cases and 86.96% of smear- and culture-negative but GeneXpert-positive cases, with an overall specificity of 90.74% among the control groups. In comparison, indirect ELISA identified only 31.48% of bacteriologically confirmed PTB cases while maintaining a high specificity of 96.15%. Receiver operating characteristic (ROC) curve analysis of RT-I-PCR assay indicated high diagnostic accuracy, with area under the curve (AUC) values ranging from 0.9741 to 0.9847. These findings highlight the potential of uEVs-based RT-I-PCR as a highly sensitive, non-invasive approach for PTB diagnosis, while emphasizing the need for further evaluation in larger and more diverse clinical cohorts to develop a scalable, non-invasive diagnostic platform suitable for TB-endemic settings.